Evidence map›Paper›PMID 38001961›Full record

ArticleBiomedicines2023

Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies.

Lars Schröder, Christian M Domroese, Alexander B A Rupp, Kathrin M E Gihr, Christoph Niederau, Michael R Mallmann, Stefan Holdenrieder

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Lars SchröderDepartment of Obstetrics and Gynecology, Medical Faculty, University Hospital Cologne, University of Cologne, 50937 Cologne, Germany.ORCID 0000-0001-6908-989X
Christian M DomroeseDepartment of Obstetrics and Gynecology, Ketteler Hospital, 63071 Offenbach, Germany.
Alexander B A RuppInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany.
Kathrin M E GihrInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany.
Christoph NiederauMVZ Labor Dortmund, 44147 Dortmund, Germany.
Michael R MallmannDepartment of Obstetrics and Gynecology, Ketteler Hospital, 63071 Offenbach, Germany.ORCID 0000-0001-9373-3331
Stefan HoldenriederInstitute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, 53127 Bonn, Germany.ORCID 0000-0001-9210-7064
University Hospital Bonn · DESana Klinikum Offenbach · DEMedizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNowadays there still is no sufficient screening tool for ovarian and uterine cancer.

objectiveThe current study aimed to investigate whether cancer antigen 125 (CA-125), tissue polypeptide antigen (TPA) or the combination of both markers are able to act as screening tools for ovarian or uterine cancer.

methodsA total of 275 blood samples from different cohorts (ovarian cancer, uterine cancer, benign control group) were prospectively drawn and analyzed.

resultsEstablished biomarkers TPA and CA-125 showed elevated serum concentrations in patients with malignant tumors as compared to healthy women and women with benign diseases. In ROC curve analyses, both biomarkers were well able to discriminate between malignant and healthy, benign or overall non-malignant cases in the whole sample, with AUCs of 0.842 and above. While TPA was the best diagnostic marker in patients with uterine cancer, CA 125 was the best in patients with ovarian cancer.

conclusionsTPA and CA-125 both showed promising results for the detection of gynecologic malignancies. The combination of CA-125 and TPA did not improve sensitivity in comparison to single markers.

Indexed as

CA 125diagnosisovarian cancerTPAtumor markeruterine cancer

Identifiers

PMID38001961
PMCPMC10669758
OpenAlexW4388231536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.